Novo Nordisk hit with FDA warning letter over acquired Catalent factory

The FDA wants Novo Nordisk to analyze all sites it bought from Catalent last year, according to a warning letter the agency sent to the drugmaker over its troubled factory in Bloomington, IN. The ...